The advancement of genomic analysis technology revolutionizes breast cancer research, as it provides better breast tumor classifications, which then leads to enhanced clinical management or precision oncology.
Clinical validation of novel RNA fusion detection for NSCLC&...
What’s New? CE-IVD Oncology Applications by SOPHiA GENETICS™...
Last week we attended the European Society for Medical Oncology (ESMO) Congress 2022, gathering the world’s leading oncologists. Read our summary of three presentations illustrating cancer therapy development.
With over 1.3 million women worldwide diagnosed with gynaecological cancers in 2020, it’s more important now than ever to equip them with tools and resources to promote prevention and early detection of potential cancers.
SOPHiA GENETICS™ is excited to be a part of the American Society of...
Cancer management outcomes can strongly benefit from robust and accurate detection of gene fusions. SOPHiA GENETICS developed the SOPHiA DDM™ Dx RNAtarget Oncology Solution to make this possible.
We list 7 reasons to consider SOPHiA DDM™ Dx RNAtarget Oncology Solution for your assays.
About Deficiency in the homologous recombination repair system represent up to 50% of the ovarian,...
About Gene fusions are the latest type of biomarker to receive broad applicability in cancer...
SOPHiA GENETICSTM is excited to be a part of the Association of Molecular...
SOPHiA GENETICSTM is excited to be a part of the European Society of Medical...
Q&A with the Clinical Application Product Manager, Mikhail Pertziger, PhD
